NeuroOne Medical Technologies Corporation — Form 10-Q
Business context and period: This filing covers the fiscal quarter and nine months ended June 30, 2020. NeuroOne is an early-stage medical-device company developing electrode and neuromodulation products for neurological disorders. It reported no commercial revenue. The company said its initial device had FDA 510(k) clearance and expected to submit a second product application by the end of calendar 2020.
Financial highlights
| Metric | Three months ended June 30, 2020 | Nine months ended June 30, 2020 |
|---|---|---|
| Revenue | None reported | None reported |
| Operating expenses | $1.59 million | $4.78 million |
| Operating loss | $1.59 million | $4.78 million |
| Net loss | $7.09 million | $13.07 million |
| Net loss per share, basic and diluted | $0.44 | $0.90 |
| Cash used in operating activities | Not separately reported for the quarter | $3.70 million |
- Cash and liquidity: Cash was $3.82 million at June 30, 2020, up from $0.26 million at September 30, 2019. Current assets were $3.90 million versus current liabilities of $8.04 million, a working-capital deficit of approximately $4.13 million. Management said available cash was insufficient to fund operations for the 12 months following the filing without additional funding.
- Debt: Convertible notes were carried at fair value of $6.73 million at June 30 and classified as current liabilities. Separately, the filing states aggregate principal and accrued interest on the 2019 and 2020 Paulson notes was $3.90 million at June 30. The notes bore 13% interest and included discounted conversion provisions. The filing recorded $7.45 million of interest expense and $2.02 million of note-extinguishment loss for the nine-month period; much of the financing-related expense was noncash.
- Cash flows and financing: Nine-month financing cash flow was $7.33 million, principally from convertible notes, partly offset by issuance costs. Investing cash use was $0.07 million. Cash increased by $3.56 million over the period.
- Margins: Operating and net margins are not meaningful because the company had no commercial revenue.
Changes versus prior comparable periods
- Quarterly net loss increased from $1.86 million in 2019 to $7.09 million in 2020, primarily reflecting new convertible-note-related interest expense and a $2.02 million extinguishment loss. Operating expenses, by contrast, declined by $0.27 million.
- Nine-month net loss increased from $5.43 million to $13.07 million. Operating expenses rose $0.32 million, including higher research and development costs; the larger increase in net loss primarily reflected financing and accounting charges associated with the 2019 and 2020 notes.
- Nine-month operating cash use improved to $3.70 million from $4.25 million, while financing proceeds lifted ending cash substantially from the prior September balance.
Outlook, commentary, risks and unusual items
- Going concern: The company disclosed substantial doubt about its ability to continue as a going concern. It has recurring losses, no established revenue source, negative working capital and a need for additional capital; failure to secure funding could force spending reductions or cessation of operations.
- Zimmer agreement after quarter-end: On July 20, 2020, NeuroOne entered an exclusive development and distribution agreement granting Zimmer global distribution rights for specified products. Zimmer paid $2.0 million upfront, triggering automatic conversion of the remaining 2020 notes; the remaining notes converted by July 23. NeuroOne remains responsible for product development and commercialization costs, while Zimmer agreed to use commercially reasonable efforts to market and sell products once available. A further SEEG-related fee may be payable after product availability. Zimmer may terminate for convenience on 90 days’ notice.
- COVID-19: The company reported delays and disruptions to preclinical and clinical trials, manufacturing, supply chain and research and development. It warned that continuing effects could adversely affect operations, liquidity and access to financing. It received approximately $83,333 under the PPP; forgiveness was uncertain.
- Regulatory and licensing: The company expected to submit a second 510(k) application by year-end 2020. Its WARF license requires minimum annual royalties of $50,000 in 2020, $100,000 in 2021 and $150,000 annually from 2022; WARF may terminate if qualifying commercial sales are not achieved by June 30, 2021, subject to the agreement’s terms.
- Litigation: In the PMT case, the court granted sanctions and partial summary judgment for the company in April 2020, while other claims remained. Trial was scheduled for May 2021 and could be affected by COVID-19; the filing does not provide a clear quantified estimate of potential exposure.
- Equity dilution: Common shares outstanding were 18.24 million at June 30 and 22.05 million as of August 10, 2020. The filing also reported 10.17 million outstanding warrants at June 30, in addition to options and other potential share issuance.
Most important facts for investors to verify
- Whether the Zimmer relationship produces product approvals, commercial availability, sales and additional payments, given NeuroOne’s continuing responsibility for development and commercialization costs.
- Current liquidity, funding needs and the company’s ability to meet obligations after conversion of the Paulson notes; reconcile the notes’ $6.73 million fair-value carrying amount with the separately disclosed $3.90 million principal and accrued-interest figure at June 30.
- Progress and timing of the second 510(k) submission, and the impact of COVID-19 on trials, manufacturing and supply chain.
- Outcome and potential financial or operational impact of the PMT litigation, and compliance with WARF license obligations and milestones.
- Potential dilution from conversions, warrants, options and future fundraising; the filing notes the 2020 Paulson note conversions continued after quarter-end.